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Heart failure (HF) is a major health problem affecting millions of patients worldwide and is 
associated with impaired quality of life and poor prognosis. Different approaches including invasive 
and non-invasive methods can be used to provide information about the cardiac performance in 
HF patients. The overall aim of this thesis was to study a number of different but complementary 
invasive and non-invasive methods that are currently used to assess cardiac performance in different 
HF phenotypes, mainly in advanced HF.
Methods and results
Study I
Twenty-three patients with advanced stable chronic HF received a single 24 h levosimendan infusion. 
Levosimendan had the following effects (median change ± SD): a significant increase in cardiac 
output (+9.8 ± 21.6%; P = 0.026) and decrease in N-terminal pro-brain natriuretic peptide (-28.1 ± 
16.3%, P < 0.001), estimated total peripheral resistance (-16.9 ± 18.3%, P = 0.004), and mean arterial 
pressure (-5.9 ± 8.2%, P = 0.007). There was no change in estimated glomerular filtration rate (+0.89 
± 14.0%, P = 0.955). No significant associations between baseline clinical and/or hemodynamic 
factors and the change in CO were found.
Study II
Levels of soluble suppression of tumorigenicity 2 (sST2) were investigated in HF with reduced 
ejection fraction (HFrEF), preserved EF (HFpEF) and in healthy controls. Crude sST2 levels were 
higher in HFrEF compared to HFpEF and controls. sST2 was associated with the composite endpoint 
of death or HF hospitalization in HFpEF, adjusted hazard ratio (HR) per log increase in sST2 6.62, 
95% confidence interval (CI) 1.04–42.28, p=0.046, and in HFrEF with death, heart transplant or left 
ventricular assist device (LVAD); 3.51, 95% CI 1.05–11.69, p=0.041.
Study III
In 192 patients with hemodynamic findings indicating HF, right heart catheterization waveforms 
were used to measure the pulsatile and steady components of the pulmonary capillary wedge pressure 
(PAWP) and to assess their impact on the pulmonary arterial compliance (PAC) and pulmonary 
vascular resistance (PVR) relationship. PAC and PVR were hyperbolically and inversely associated. 
In the patient cohort with higher pulsatile PAWP component, there was a significant downward and 
leftward shift of the PAC-PVR curve fit. The steady PAWP component did not impact significantly 
on the PAC-PVR relationship. 
Study IV
Data from 14 LVAD patients assessed by echocardiographic ramp test was retrospectively reviewed. 
Adequate left ventricular (LV) unloading was defined as no more than mild mitral regurgitation, and 
intermittent aortic valve (AV) opening or closed AV, and reduction of LV end-diastolic diameter, and 
for the follow-up measurement, decreased NT-proBNP. Ramp testing resulted in final LVAD speed 
increase in 79% of patients and a median net change of 200 (200; 300) revolutions per minute. Speed 
adjustments after ramp testing resulted in improved LV unloading in additional 21% of patients who 
were not originally optimized. Right ventricular function did not worsen. 
Conclusion 
By assessing hemodynamics, echocardiography and biomarkers, it is possible to gain a better 
understanding of the different HF phenotypes and the underlying physiology, which may help 
to optimize care and introduce potential targets for therapy. 
1. ABSTRACT




Hjärtsvikt är en vanlig sjukdom som leder till försämrad livskvalitet och sämre prognos. 
Olika metoder kan användas för att utvärdera hjärtfunktionen hos hjärtsviktpatienter. Syftet 
med avhandlingen var att studera olika invasiva och non-invasiva metoder för att kartlägga 




23 patienter med avancerad, stabil hjärtsvikt fick levosimendaninfusion i 24 timmar. 
Blodprover och hjärtfunktion utvärderades före och efter infusionen. Levosimendan hade 
positiva hemodynamiska effekter efter bara en infusion men inga prediktorer för den positiva 
effekten kunde identiferas.
Studie II
I en retrospektiv analys av patienter med hjärtsvikt med sänkt (HFrEF) och bevarad 
(HFpEF) ejektionsfraktion undersöktes nivåer av Suppression of tumorigenicity (sST2) och 
associationer med kliniska parametrar och outcome. Patienter med HFpEF hade lägre nivåer 
av sST2 jämfört med HFrEF. Högre sST2 nivåer var associerade med svårare hjärtsvikt och 
sämre prognos i båda hjärtsviktstyperna.
Studie III
Hos 192 patienter med HFpEF och HFrEF studerades data från hjärtkaterisering för att 
utvärdera effekten av de olika komponenterna av wedgetryck (PAWP) på relationen mellan 
pulmonell arteriell compliance (PAC) och resistans (PVR). Vi bekräftade den tidigare kända 
påverkan av PAWP på PAC-PVR förhållandet och vi visade att den pulsatila komponenten i 
PAWP hade  större betydelse än den statiska.
Studie IV
Ekokardiografiskt ramp-test utfördes på 14 patienter med vänsterkammarassist (LVAD) 
1-3 månader postoperativt för att se om avlastning av vänsterkammare hos patienter med 
LVAD kan förbättras med ekokardiografisk utvärdering (ramp-test). Ramp-testet bidrog 
till justering av pumphastighet och optimering av hemodynamik utan försämring av 
högerkammarfunktionen.
Slutsats
Invasiva och icke-invasiva metoder kan användas i olika typer av hjärtsvikt för att få bättre 
uppfattning om patofysiologin och bättre kunskaper om prognosen och behandlingen.
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4. ABBREVIATIONS
ACEI                                               Angiotensin-converting enzyme inhibitor
ADHF Acute decompensated heart failure
ARB Angiotensin receptor blocker
ARNI                                               Angiotensin receptor neprilysin inhibitor
AV Aortic valve
BMI Body mass index
BSA                                                Body surface area




CKD-EPI Chronic Kidney Disease Epidemiology Collaboration 
CRT                                                  Cardiac resynchronisation therapy 
CV Coefficient of variation
CVP                                        Central venous pressure
DT Destination therapy
E/e’ Left ventricular transmitral early diastolic filling velocity/
left ventricular early diastolic myocardial velocity
EF                                     Ejection fraction
eGFR Estimated glomerular filtration rate 
eTPR Estimated total peripheral resistance
HF Heart failure
HFmrEF Heart failure with mid-range ejection fraction 
HFpEF Heart failure with preserved ejection fraction
HFrEF Heart failure with reduced ejection fraction
HR Hazard ratio 
HRAEs Hemocompatibility-related adverse events  
HTx Heart transplantation
Innocor® Inert gas re-breathing method
ICD Implantable cardioverter defibrillator
IVC Inferior vena cava       
KaRen  Karolinska-Rennes Study
LA Left atrium
LAP Left atrial pressure




LVAD Left ventricular assist device
LVEDD Left ventricular end-diastolic diameter
LVMi Left ventricular mass index
MAP Mean arterial pressure
MR Mitral regurgitation
MRA Mineralocorticoid receptor antagonist 
NPs Natriuretic peptides
NT-proBNP N-terminal pro-brain natriuretic peptide
NYHA New York Heart Association
PAC Pulmonary arterial compliance 
PAP Pulmonary artery pressure
PAPD Diastolic pulmonary artery pressure
PAPM Mean pulmonary artery pressure
PAPS Systolic pulmonary artery pressure
PAWPM Mean pulmonary capillary wedge pressure
PAWPp Pulsatile PAWP
PAWPs Steady PAWP
PBF Pulmonary blood flow 
PH   Pulmonary hypertension 
PVR Pulmonary vascular resistance  
RAAS Renin angiotensin aldosterone system
RC-time          Time-constant of the pulmonary circulation
RHC                                         Right heart catheterization                                                                                          
RPM Revolutions per minute 
RV Right ventricle 
RVEDD Right ventricular end-diastolic diameter  
SNS Sympathetic nervous system
ST2    Suppression of tumorigenicity
SV Stroke volume
TAPSE Tricuspid annular plane systolic excursion 
TR Tricuspid regurgitation   
Q1 Lower quartile
Q3      Upper quartile
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5. INTRODUCTION
5.1 General aspects of heart failure
Definition
Heart failure (HF) is defined by the European Society of Cardiology (ESC), as “a clinical 
syndrome characterized by typical symptoms (e.g. breathlessness, ankle swelling and 
fatigue) that may be accompanied by signs (e.g. elevated jugular venous pressure, pulmonary 
crackles and peripheral oedema) caused by a structural and/or functional cardiac abnormality, 
resulting in a reduced cardiac output (CO) and/or elevated intracardiac pressures at rest or 
during stress.” (1). 
Cardiac performance is dependent on heart rate, contractility, preload, and  afterload and both 
diastolic and systolic function must be maintained for normal cardiac function (2). However, 
much of HF research and therapy has focused on systolic dysfunction, partly due to the 
widespread use of reduced left ventricular (LV) ejection fraction (EF) for diagnosing HF in 
clinical practice, acceptance of EF as a predictor of prognosis in HF patients, and the use 
of EF for selecting patients into clinical trials of HF therapy (3). Studies in the early 2000s 
explored the impact of normal or mildly reduced EF in HF patients and initially diastolic 
and systolic HF were considered as distinct phenotypes within the HF spectrum (4, 5). The 
echocardiographic Recommendations for chamber quantification from 2005 recommended 
the assessment of the LV diastolic function and considered left atrial (LA) enlargement as 
a marker of both the severity and chronicity of diastolic dysfunction and magnitude of LA 
pressure (LAP) elevation (6).
Current classification
In 2016, a new classification of chronic HF was proposed by the ESC, based on EF; HF with 
reduced EF (HFrEF) where EF is <40%, mid-range EF (HFmrEF) with EF 40-49%, and 
preserved EF (HFpEF) where EF is ≥50%. The old nomenclature of systolic and diastolic 
HF is abandoned in the current guidelines since diastolic dysfunction can exist throughout 
the EF spectrum, and vice versa, since systolic function is not necessarily normal in HFpEF 
(1). According to the ESC guidelines and contemporary trials, the diagnosis of HFmrEF and 
HFpEF also requires elevated natriuretic peptides (NPs) and relevant structural or functional 
heart disease such as LV hypertrophy, LA enlargement, and/or diastolic dysfunction. 
However, the precision and reproducibility of echocardiography, the most frequently used 
imaging modality to assess EF in these patients, is probably not good enough to categorize 
HFrEF, HFpEF, and HFmrEF reliably and reproducibly (7, 8). 
Advanced HF
HF is a progressive clinical syndrome and many HF patients ultimately progress to advanced 
HF, refractory to evidence-based therapies (9). Patients with advanced HF comprise an 
estimated 5 % of the overall HF population but the prevalence is increasing along with the 
ageing population as well as due to more efficient therapies in ischemic heart disease and HF 
leading to improved survival (10, 11). Prior definitions of advanced HF have changed since 
2007 when the Heart Failure Association (HFA) identified advanced HF as a stage where 
conventional therapies were insufficient to control the patient’s symptoms, and advanced 
treatments [heart transplantation (HTx) or mechanical circulatory support] or palliative 
therapies (e.g. inotropic agents, ultrafiltration or peritoneal dialysis to control volume, or 
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end-of-life measures) were needed (12). In the new HFA statement, the previous definition of 
advanced HF has been revised to acknowledge the importance of HFpEF (13). The current 
guidelines include the following criteria for defining advanced HF: [1] Severe and persistent 
symptoms of HF [advanced New York Heart Association (NYHA) class III or IV], [2] 
severe cardiac dysfunction defined according to the ESC criteria, to include all HF patients 
independent of EF, [3] pulmonary or systemic congestion episodes, episodes of low output 
requiring inotropes/vasoactive drugs, malignant arrhythmias causing >1 unplanned visit or 
hospitalization in the last year, and [4] severe impairment of exercise capacity (13).
Pathophysiology
Controversy remains as to whether HFpEF is the same disease as HFrEF albeit with preserved 
EF, if HFpEF is an entirely distinct entity with different pathophysiologic background, or 
finally if it is merely a consequence of ageing and related comorbidities (14-16). However, 
a prevailing view is that myocardial remodeling in HFrEF is driven by loss of myocardial 
function secondary to an initial injury, e.g. myocardial infarction, which triggers maladaptive 
neuro-hormonal activation [sympathetic nervous system (SNS), renin angiotensin aldosterone 
system (RAAS), and antidiuretic hormone (ADH)], causing increased load, myocardial 
remodeling including LV dilatation, and eccentric hypertrophy leading to manifest HF. In 
contrast, in HFpEF, a systemic pro-inflammatory state induced by comorbidities is believed 
to lead to endothelial damage and microvascular dysfunction through decreased nitric oxide 
and cyclic guanosine monophosphate, which ultimately results in concentric LV remodeling 
and reduced myocardial compliance (17), Figure 1. This new paradigm is mainly supported 
by the different patterns of structural and functional changes in HFpEF compared to HFrEF, 
and the disappointing results of previous trials employing neurohormonal antagonists in 
HFpEF (1, 18-20). Nevertheless, neurohormonal activation exists in both HF entities, but it 
is thought to play a less dominant role in HFpEF.
Figure 1. Overview of the pathogenesis in HFpEF and HFrEF. 
Heart, Lam CSP, Lund LH, 2016, reproduced with permission from the publisher.
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Epidemiology and prognosis
HF is a major and growing public health problem, affecting millions of patients worldwide 
with a prevalence and incidence of 3% and 0.5% respectively (21, 22).  HF prevalence is rising 
to ≥10% among people >70 years of age (23, 24) and is estimated to increase by 25% by 2030 
(25). While HFrEF incidence is declining in the last decade due to effective revascularization 
of patients with acute coronary syndromes (26, 27), the prevalence and incidence of HFpEF, 
is increasing due to improved recognition and an ageing population (28).
HF is the leading cause of hospitalization in patients >65 years (29), and is associated with 
severely compromised quality of life (30, 31), poor prognosis (32-34), and high socioeconomic 
burden (35). An analysis of the ESC Heart Failure Long-Term Registry described 1-year 
mortality in ambulatory HF patients in Europe, stratified by EF (HFrEF 8.8% , HFpEF 
6.3%, and with HFmrEF intermediate, 7.6%) (36). Among patients hospitalized with HF, 
patients across the EF spectrum have a similarly 5-year mortality HFrEF (75.3%) vs. HFpEF 
(75.7%) vs. HFmrEF 75.7% with an increased risk for cardiovascular and HF admission (37). 
Repeated HF hospitalizations is a strong predictor of  mortality and approximately half of 
patients will be dead by 1 year after 3 hospitalizations (38). 
Treatment
HFrEF: Blocking the SNS and the RAAS has been the corner stone of modern HFrEF 
treatment since the CONSENSUS trial from 1987 which showed that the angiotensin 
converting enzyme inhibitor (ACEi) Enalapril vs. placebo reduced mortality by 27%  in 
NYHA IV (39). Even the use of angiotensin receptor blockers (ARB) in patients intolerant 
to ACEi reduced cardiovascular mortality and morbidity (40). Similarly, the use of beta-
blockers also showed a positive effect on mortality in different trials (CIBIS II, MERIT-HF, 
COPERNICUS) (41-43). The treatment with mineralocorticoid receptor antagonist (MRA) 
Spironolactone, an aldosterone antagonist blocking the RAAS, resulted in an incremental 
mortality reduction of 30% when added to ACEi in patients in NYHA class III-IV (44). 
In 2014, a new agent was introduced targeting the endogenous compensatory adaptive 
responses in HF, namely; the angiotensin receptor neprilysin inhibitor (ARNI) which reduces 
the degradation of vasoactive peptides (45) including natriuretic peptides, bradykinin and 
adrenomedullin. Since then a new strategy has been used to treat HFrEF based on inhibiting 
the maladaptive compensatory responses and enhancing the endogenous compensatory 
responses. 
Interestingly, novel antidiabetic agents known as sodium-glucose cotransporter 2 inhibitors 
(SGLT2i) which act by inhibiting glucose reabsorption in proximal convoluted tubules of 
kidney were shown to reduce the risk for cardiovascular death and worsening HF among 
adults with HFrEF regardless of diabetes status (46). More recently, Vericiguat which is a 
novel class of drug targeting the nitric oxide (NO) pathway by stimulating the NO receptor 
soluble guanylate cyclase (sGC), has shown to reduce the risk of the composite endpoint of 
HF hospitalisation or cardiovascular death, compared to placebo in patients suffering from 
worsening chronic HFrEF in the VICTORIA trial (47).
Cardiac resynchronization therapy (CRT) and implantable cardioverter-defibrillators (ICDs) 
improve outcomes in selected patients with HFrEF in multiple clinical trials (48-51); however, 
the benefit of ICD in patients with CRT is less certain (51).
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HFpEF: There is yet no evidence-based therapy in HFpEF and previous trials of ACEi, ARBs, 
beta-blockers, and MRA have all been disappointing and failed to show improved survival 
(1, 52-55). Recently the use of ARNI has failed to reduce the incidence of cardiovascular 
death or hospitalization for HF compared with valsartan in HFpEF (56). The current ESC 
guidelines recommend the treatment of coexisting comorbidities and measures to reduce 
symptoms from volume overload. 
HFmrEF is increasingly recognized as phenotypically more similar to HFrEF, and post-
hoc analyses from CHARM-Preserved (57), TOPCAT (58), and a beta-blocker meta-analysis 
(59), as well as from a sub-group analysis in PARAGON-HF (56), suggest that conventional 
HFrEF therapy may be effective also in patients with mildly reduced EF, patients that 
previously and for trial purposes were considered to have HFpEF.
Advanced HF therapy
Inotropic agents
Advanced HF therapies include durable long-term mechanical circulatory support devices 
(MCS) or HTx. However, in situations where the patient’s clinical condition deteriorates, or 
end-organ function is compromised, short-term therapies like inotropic agents may be needed 
until MCS can be implanted or while the patient is waiting on the transplant list (13).
Intravenous inotropes (milrinone, dobutamine and dopamine) improve hemodynamics and 
end-organ perfusion and relieve symptoms, but due to short half-lives, they are limited to 
selected in-patients and may be associated with increased mortality (60-64).
Long-term or chronic treatment with inotropes for patients waiting for HTx is not routinely 
recommended. However, continuous or intermittent out-patient inotrope infusions may be 
required to prevent hospitalization and preserve perfusion and end-organ function, especially 
those who may not be suitable for bridging with left ventricular assist device (LVAD) (13). 
Yet, this practice is controversial and may also be associated with increased mortality (65-67).
Levosimendan is a relatively novel inotropic agent that was approved in Europe in the 2000s 
for the treatment of acute decompensated advanced HF (ADHF). It is not licensed in the 
USA. Its positive hemodynamic effect may last for >7 days after a 12–24 h infusion because 
of the pharmacologically active metabolite with a long half-life (68). Levosimendan is an 
intravenous inodilator agent which main effect is mediated partly by calcium sensitization, 
purportedly without concomitant increase in myocardial metabolic demand or intracellular 
calcium levels (69, 70). In early studies in ADHF, levosimendan improved hemodynamics 
and mortality compared to dobutamine (71) and placebo (72). In later studies, it was not 
superior to dobutamine (73), and improved symptoms but increased hypotension and 
arrhythmia compared to placebo (74).
Intermittent use of levosimendan for long-term symptomatic improvement or palliation 
has gained popularity in the last decade and meta-analyses of several small trials of a 
repeated infusion strategy have suggested a positive effect on survival and a reduction in 
hospitalizations (75, 76). Even the LION-HEART pilot study that randomized 69 patients 
with advanced HF to placebo or levosimendan over 6 hours every 2 weeks for 12 weeks 
showed a significantly lower NT-proBNP over time in the levosimendan group compared 
to the placebo group (77). However, the beneficial effects of repetitive levosimendan use in 
advanced HF are still uncertain and a positive survival effect needs to be demonstrated in 
adequately sized, prospective studies.
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Mechanical circulatory support and heart transplantation
For patients with advanced HF, HTx remains the best therapeutic option with 1-year survival 
of almost 90 % and median survival of 12.2 years. The number of HTx procedures are 
nevertheless stagnant due to shortage of donors (78). Although randomized controlled trials 
have never been conducted for HTx, there is overwhelming consensus within the cardiology 
community that HTx significantly improves survival, exercise capacity, and quality of life, 
provided that proper selection criteria are applied (1, 13). However, HTx is still challenged 
by limited effectiveness and complications of immunosuppressive therapy (e.g. infections, 
cardiac allograft vasculopathy, antibody-mediated rejection, late graft dysfunction, and 
malignancy) (78). 
The use of durable MCS like LVADs in advanced HF has increased during the last decade 
due to organ shortage and advances in bioengineering (13, 79, 80). LVADs can be used as 1) 
destination therapy (DT) meaning permanent therapy for patients with contraindications for 
HTx, 2) as a bridge to transplantation (BTT) to maintain end-organ perfusion and increase 
the chance of survival while waiting for a HTx, 3) as a bridge to decision (BTD) to allow 
time for full clinical evaluation for HTx, 4) as a bridge to candidacy (BTC) to improve end-
organ function like renal function or reverse contraindications like high pulmonary vascular 
resistance (PVR) in order to become eligible for HTx, and 5) as bridge to recovery (BTR) 
as in cases of myocarditis where cardiac recovery is facilitated by LVAD unloading together 
with intensive neurohormonal blockade, leading to reverse remodeling (81).
LVADs improve survival, functional capacity, and quality of life in appropriately selected 
HF patients (82-84). However, LVADs are still limited by complications like infection, 
right ventricular (RV) failure, and hemocompatibility-related adverse events (HRAEs) like 
thrombosis, stroke, and bleeding (85-87) despite the production of more hemocompatible 
devices; namely, HeartMate 3 (HM3) LVAD (Abbott, Lake Bluff Illinois) (88). 
The landmark trial for LVADs as destination therapy as compared to medical therapy is The 
Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart 
Failure (REMATCH) trial from 2001. REMATCH showed improved 1-year survival of 
52% in inotrope-dependent, transplant-ineligible patients with advanced HF treated with an 
LVAD, but 2-year survival of 23% was not statistically different (89). Since then, the one-
year survival with LVAD has improved to >80% (82) mainly due to better patient selection, 
improved surgical techniques, and post-operative care. 
5.2 Biomarkers in HF
What we usually refer to as biomarkers are any measurement associated with a biological 
state, but more narrowly and more commonly, a group of biological substances (like 
hormones, enzymes and genes) that can be objectively measured in blood or tissue and act as 
indicators of normal biologic processes, pathogenic processes, or responses to a therapeutic 
intervention (90). The most commonly utilized biomarkers in HF belong to the natriuretic 
peptide (NP) family which includes a large number of peptides and peptide fragments, 
related to e.g. A-type NP, B-type NP (BNP), and C-type NP (91). BNP and its amino-terminal 
cleavage fragment (NT-proBNP) are the most clinically used biomarkers in HF and are 
derived from the pro-enzyme proBNP, primarily released from ventricular cardiomyocytes 
in response to an increase in ventricular wall tension and are valuable for the diagnosis (92, 
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93), prognosis (94, 95), and may potentially improve HF management when used as serial 
measurements guiding therapeutic interventions (96, 97). BNP has many biological functions 
such as vasodilation, diuresis, and natriuresis, which represent compensatory mechanisms 
that counteract the activation of the RAAS and SNS in HF patients (98). Nevertheless, their 
use is limited by the fact that the levels typically rise and fall in parallel with hemodynamic 
measurements such as left ventricular end-diastolic pressure, i.e. they only give us an insight 
into one of the different mechanisms that are involved in the development of HF namely 
myocyte stress/stretch (99). Furthermore, NPs discriminate well, i.e. differentiate risk, but do 
not calibrate well, i.e. there is no universal cut-off or criterion that can be used for specific 
decisions, such as who to list for heart transplantation. Plasma levels of BNP and NT-proBNP 
are furthermore influenced by sex, age, renal function, pulmonary disease, and obesity 
(100-102). Higher BNP/NT-proBNP levels are associated with severity of HF and worse 
prognosis in both the acute and chronic setting across all EF phenotypes (103-105), however, 
normal BNP is sometimes found in patients with HFpEF despite increased filling pressures, 
particularly those with elevated filling pressures at exercise but not at rest (106).
The exploration of novel applications of established biomarkers and research on new reliable 
biomarkers that reflect different pathophysiological pathways and markers of potential 
therapeutic targets in HF have been expanding over the last decades (107). An example of 
such new biomarkers is Galectin-3, secreted by activated macrophages and closely associated 
with cardiac remodelling. Galectin-3 level is usually elevated in HF patients, associated 
with prognosis but is inferior to BNP and NT-proBNP at diagnosing HF (108, 109). Another 
example is Adrenomedullin (ADM), which is expressed in all body tissues and reflects the 
neurohormonal activation pathway. ADM has vasodilative, antiproliferating, and inotropic 
effects (110). ADM activation is more accurately reflected by its stable precursor fragment 
mid regional pro-ADM. ADM levels are elevated in HF and correlate to disease severity 
but has limited clinical application due to instability and short half-life in plasma (111-113). 
A third example is growth differentiation factor-15 (GDF-15), a marker of cell injury and 
inflammation (114). Elevated GDF-15 level is strongly related to NYHA class in HF and 
serve as a strong predictor of all-cause mortality in HFrEF and HFpEF (115, 116).
5.3 Supression of tumorigenicity 2
Suppression of tumorigenicity 2 (ST2) is a member of the interleukin (IL) 1 receptor family 
and has two main isoforms: a transmembrane receptor (ST2L) and a soluble receptor that 
can be detected in plasma (sST2) (117). It was first described in 1989 in inflammatory and 
autoimmune diseases (118, 119), is secreted by many cells in response to damage (120) and is 
part of a cardioprotective signaling system. When the ligand for ST2, Interleukin 33 (IL-33) 
is bound to ST2L, IL-33 exerts anti-fibrotic and anti-hypertrophic effects while the presence 
of sST2 inhibits these beneficial effects by neutralizing the beneficial activity of circulating 
IL-33 and thus leading to fibrosis (121, 122). Interestingly, sST2 is markedly induced in 
mechanically overloaded cardiac myocytes and reflects myocardial stress, ventricular 
remodelling, and fibrosis (123). Unlike NPs, it reflects not only load but also inflammatory 
and fibrotic pathways (124). sST2 is elevated in various cardiovascular conditions such as 
worsening of previous chronic HF, new onset HF, and myocardial infarction. However, 
its diagnostic ability for acute HF is inferior to NT-proBNP making sST2 less used as a 
diagnostic tool for HF (125). On the other hand, in acute HF independent of EF and in 
chronic HFrEF patients, sST2 levels are strongly associated with the severity of HF and are 
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strong and independent predictors of mortality (126-128). Interestingly, serial measurement 
of sST2 with higher levels at follow-up predict mortality in acute and chronic HF independent 
of natriuretic peptides (129-131). sST2 is less studied in HFpEF, especially in patients with 
chronic HFpEF (132-134).
The pathway of ST2 and its ligand IL-33 has emerged as a novel area of interest in HF 
and may be a therapeutic target in the prevention and treatment of cardiovascular diseases 
including HF (124, 135, 136). 
5.4 Cardiovascular hemodynamics
5.4.1 Right heart catheterization
Right heart catheterization (RHC) is a widely used invasive procedure providing direct and 
accurate measurements of hemodynamics of the cardiovascular system. It was performed for 
the first time by Forssmann in 1929 (137). RHC enables direct and accurate assessment of the 
pulmonary and right heart pressures as well as an indirect yet accurate measurement of the 
left atrial pressure (LAP). Quantification of CO and PVR are critical components of invasive 
hemodynamic assessment. RHC is most commonly used in the following conditions: 1) 
diagnosis and differentiation of pulmonary hypertension (PH), 2) assessment of eligibility 
for LVAD, and heart and/or lung transplantation 3) evaluation prior to correction of cardiac 
shunt defects (138-140).
It is usually carried out using a 6F balloon-tipped fluid-filled Swan-Ganz catheter through 
the internal jugular vein. Mean right atrial pressure, pulmonary artery pressures (PAP), 
pulmonary capillary wedge pressure (PAWP) and RV systolic pressure are usually recorded 
under fluoroscopy at end-expirium during spontaneous breathing after calibration with the 
zero-level set at the mid-thoracic line, Figure 2. Thermodilution or Fick are usally used to 
measure CO (141-143).
Figure 2. Illustrates RHC and normal pressure waves, https://www.cvphysiology.com, 
reproduced with permission from the publisher.
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In general, the RHC is more time consuming and associated with a risk for complications. In 
the acute and advanced HF setting, trials suggest that RHC does not improve outcomes (126, 
127), but it remains widely used particularly in the intensive care setting. For these reasons, 
non-invasive techniques, e.g. inert gas rebreathing (Innocor®, Innovision A/S, Denmark) and 
echocardiography, have been developed to assess CO.
5.4.2 Cardiac output 
CO is the amount of blood pumped by the heart in one minute and is the product of heart rate 
(HR) and stroke volume (SV). The SV is the amount of blood ejected during each ventricular 
contraction and is dependent on preload, contractility, and afterload (144). 
Various methods can be used to measure the SV and CO; some of them are invasive like 
angiography and cardiac catheterization (Direct Fick method, dye dilution or thermodilution) 
while others are non-invasive like echocardiography, cardiac magnetic resonance imaging, 
and inert gas rebreathing such as with the Innocor® device. 
The direct Fick method is often considered the gold standard for the quantification of CO and 
is based upon measurements of the oxygen uptake together with calculation of the difference 
in oxygen saturation between arterial and venous blood. However, the clinical use of the Fick 
technique is less practical and the development of the thermodilution technique made this 
method the practical gold standard in the cardiac catheterization laboratory and intensive 
care settings (144). 
5.4.3 Echocardiography
Assessment of the LV systolic and diastolic functions is the most clinically important task of 
echocardiography because of the potential association between all forms of heart disease and 
abnormalities of LV function, and because of the use of EF for determining indications for 
evidence based HF therapy. The difficulty in assessing the LV systolic function is related to the 
complexity of the heart, which is always in a dynamic state. Moreover, cardiac performance is 
continuously influenced by the prevailing hemodynamic conditions i.e. preload and afterload 
(145). Several echocardiographic approaches can be used to evaluate the LV systolic function. 
The most commonly used is the measurement of EF, which represents the proportion of blood 
within the LV that is ejected during each cardiac cycle. The biplane modified Simpson’s rule 
is the recommended method for determining LV volumes and EF, taking into account the 
ventricular geometry by measuring LV cavity area in 2 planes perpendicular to each other (6).
Other echocardiographic methods to determine the LV systolic function include determination 
of the SV by Doppler echocardiography, the use of tissue Doppler, the use of strain 
echocardiography, and the determination of the intraventricular pressure changes during 
early systole (dP/dt) (146-149). 
Echocardiographic assessment of LV diastolic function is also an integral part of the routine 
evaluation of patients presenting with symptoms of dyspnea or HF and the current guidelines 
recommend a number of parameters to grade diastolic dysfunction and to estimate LV filling 
pressures (150).
5.4.4 Inert gas rebreathing method
Innocor® (Innovision A/S, Denmark) is an established, safe and non-invasive inert gas 
rebreathing technique used for assessing CO, pulmonary blood flow (PBF), SV, and other 
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parameters and is based on the  Fick principle (151), Figure 3.  The Innocor® uses a gas 
mixture of two inert gases in a closed rebreathing system; one completely and immediately 
blood soluble (nitrous oxide) and one insoluble (sulfur hexafluoride). The soluble gas 
dissolves in the blood of the lung capillaries and is subsequently washed out by the blood 
perfusing the lungs. The PBF, which in the absence of shunting equals CO, is proportional 
to the rate by which the soluble gas is washed out and is measured by a photoacoustic gas 
analyser. The insoluble gas is used to determine the lung volume needed for the calculation 
of the CO. This technique has been shown to correlate well with invasive measurements of 
CO (direct Fick, thermodilution and dye dilution), to be safe, easy to use, and comfortable for 
the patients in different clinical settings (152-154).
5.4.5 The cardiopulmonary unit
Increased RV afterload is the main pathophysiologic mechanism for RV failure and is 
mainly caused by LV systolic or diastolic dysfunction. Essentially all myocardial diseases 
involving the left heart and independent of EF may affect RV function like myocardial 
ischaemia/infarction, myocarditis/septic cardiomyopathy, takotsubo cardiomyopathy, dilated 
cardiomyopathy, and hypertrophic cardiomyopathy (155, 156).
The RV and the pulmonary vascular system are referred to as the cardiopulmonary unit where 
there is an interaction between the ventricular pump and its afterload (157). The RV afterload 
is composed of resistive and elastic components. The resistive component represents the 
opposition to forward flow and is usually described as the pulmonary vascular resistance 
(PVR) while the elastic component represents the energy required to overcome increased 
systolic pressure during ejection and is often evaluated using pulmonary arterial compliance 
(PAC) (158, 159). 
Figure 3. Measuring CO using Innocor®, http://www.innocor.dk/#Product, reproduced 
with permission from the publisher.
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In clinical practice and trials, PVR is usually used to describe the RV afterload and the 
potential improvement following a specific therapy. However, using only PVR to determine 
RV afterload is an inaccurate measure since it does not include the contributions of the elastic 
component (160, 161). Moreover, PAC decreases earlier in the disease process, when PVR 
is still normal (161). 
Previous studies have shown that there is an inverse and hyperbolic relationship between PAC 
and PVR and advocated for a constancy of their product (RC-time) (162-165). This RC-time 
constancy has been previously explained by the contribution to PAC by the vessels responsible 
for PVR (163). In addition, increased PVR will lead to increased pressure (Ohm’s law), which 
will lead to a decrease in PAC by a shift in position on the pressure-volume relationship of 
the large pulmonary artery (165). This general rule of constancy has been questioned and a 
number of modifying factors have been suggested to reduce RC-time like increasing age, 
increased pulmonary capillary wedge pressure (PAWP) and exercise (166-168). 
5.4.6 Ramp test to optimize LV unloading
A key element in the postoperative management of LVAD patients is to optimize pump 
speed in order to achieve LV unloading, optimal hemodynamics and to reduce LVAD-related 
complications (169, 170).  Echocardiography-guided LVAD speed optimization protocols 
(Ramp test) entail a gradual increase of the LVAD speed by 100-400 revolutions per minute 
(RPM) at 1-2 minute intervals with repeated acquisition of all echocardiographic and device 
parameters at each speed step in order to optimize pump speed and thus achieve adequate LV 
unloading (169, 171). 
The current echocardiography guidelines do not recommend echocardiography-guided ramp 
test as a standard protocol for postoperative follow-up due to lack of evidence of impact on 
the short- and long-term clinical outcomes (172), and there are still significant differences 
in assessment and management of LVADs between hospitals. On the other hand, invasive 
hemodynamic ramp testing by RHC appears to potentially increase the likelihood of 
achieving optimal hemodynamics, and reduce readmission rates (173), reduce HRAEs (174), 
and improve functional capacity assessed by 6-minute walk distance (175). 
However, it is still a controversial issue whether to routinely use echocardiographic ramp 
test or invasive hemodynamic ramp test and there is an ongoing trial (The Ramp-it-Up 
study, Unique identifier: NCT03021239, https://www.clinicaltrials.gov) trying to answer this 
question by randomizing patients to speed optimization using either echocardiography or 
invasive hemodynamic catheterization. 
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6. AIMS
The overall aim of this thesis was to study a number of different but complementary invasive 
(RHC) and non-invasive methods (sST2, echocardiography, and Innocor®) that are currently 
used to assess cardiac performance in different HF phenotypes, mainly in advanced HF. 
Specific aims were:
Study I
To assess whether a single infusion of levosimendan improves non-invasively measured 
hemodynamics in advanced, stable chronic HF, and whether the response is dependent on 
baseline clinical and hemodynamic factors.
Study II
To assess sST2 concentrations and associations with other biomarkers, echocardiographic 
measures of diastolic and systolic function, and outcomes in HFpEF and HFrEF.
Study III
To assess the differential impact of the steady and pulsatile components of the PAWP on the 
PAC-PVR relationship in HF patients using RHC.
 
Study IV
To test if echocardiographic ramp test post LVAD implantation improves LV unloading and 
if speed adjustment worsen RV function immediately after and 1-3 months after a ramp test 
as compared to before the test.
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7.THESIS AT A GLANCE
Study I II III IV
Design Cohort study Cohort study Cohort study Cohort study
Data source Patients scheduled for 
elective intravenous 
levosimendan 
infusion at Karolinska 
University Hospital
KaRen, MetAnEnd Patients referred for 
diagnostic RHC at 
Karolinska University 
Hospital
Patients followed at 
Karolinska University 
Hospital after LVAD 
implantation





Study population Advanced stable 
chronic HFrEF with 
NYHA III-IV and EF 
<40%
Chronic HFpEF, HFrEF 
and healthy controls 
Patients with 
hemodynamic 
findings indicating HF 
defined as elevated 
LAP at rest or during 
exercise (PAWP rest 
>15 mmHg, PAWP 
exercise ≥23 mmHg)  
Patients with LVAD 
undergoing an 
echocardiographic 
ramp test pre 
discharge or as 
outpatient
Principal  method Innocor® sST2 RHC Echocardiography
Numbers included 
in analyses
N=23 N=193 (HFpEF: 86, 











death from any cause
HFrEF: 
Transplantation, LVAD 
or death from any 
cause













Mann-Whitney U test Wilcoxon’s paired test
Results/
Conclusions
In patients with 






no predictors of 
response could be 
identified. 
In patients with 
HFpEF compared 
to HFrEF, levels of 




The pulsatile rather 
than the steady PAWP 
component stands 
for the previously 
documented PAWP 
impact on the PAC-




tests improved LV 
unloading with no 
evidence of worsening 
of RV function. 
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8. METHODS
8.1 Study population/data sources
8.1.1 Study I
Patients with advanced but not acutely decompensated HFrEF with NYHA III and IV 
symptoms and an LVEF of < 40% were included. They were scheduled for elective intravenous 
levosimendan infusion based on consensus clinical indication at the Karolinska University 
Hospital. Patients were either listed for or undergoing evaluation for HTx or LVAD, or in 
palliative care. 
8.1.2 Study II
Patients with HFpEF were obtained from the Karolinska Rennes (KaRen) study, which 
was a prospective, bi-national, observational, multicenter study enrolling patients in France 
and Sweden during 2007-2011. The primary aim was to examine the role of electrical 
dyssynchrony in patients with HFpEF. The KaRen Biomarker Study (Study II) was a pre-
specified sub-study including Swedish sites. 
Patients were included at hospital presentation for acute decompensated HFpEF 
with symptoms and signs of acute HF, NT-proBNP >300 ng/L and LVEF ≥45% (by 
echocardiography during the first 72 h).  The patients returned to the hospital in a stable 
condition 4–8 weeks after enrolment for a follow-up visit including blood samples, clinical 
assessment and echocardiography and were then followed until September 2012 whereupon 
patient’s status was assessed by chart review, telephone contact or by the Swedish National 
Patient and Population Registers. The primary outcome was a composite of death from any 
cause or hospitalization for HF (176). 
Patients with HFrEF with LVEF <40%, were recruited from referrals to Karolinska 
University Hospital for advanced assessment of HF between January 2009 and September 
2014 (The Metabolic Anabolic Endothelial Function Heart Failure study cohort (MetAnEnd-
HF)). Exclusion criteria were inability to participate or participation in a pharmacological 
intervention study. Blood samples were collected and clinical assessment including 
echocardiography was performed at enrolment and outcome data was obtained from chart 
review and the Swedish National Patient and Population Registers. The primary composite 
endpoint in this group was death from any cause, implantation of LVAD or HTx.
8.1.3 Study III
Patients undergoing diagnostic RHC at Karolinska University Hospital for unexplained 
dyspnea, suspected PH or for assessment prior to decision for HTx or LVAD were included 
and studied between February 2014 and August 2018. The study population included 192 
patients with hemodynamic findings indicating HF, defined as elevated LAP at rest or during 
exercise (PAWPrest >15 mmHg, PAWPexercise ≥23 mmHg).   Patients with normal RHC, 
pre-capillary PH, constrictive pericarditis, arrythmogenic RV cardiomyopathy, and post HTx 
were excluded. A complete echocardiographic examination and RHC were performed during 
the same day. All participants provided morning, fasting blood samples.
8.1.4 Study IV
We retrospectively reviewed data from 14 patients followed at the Karolinska University 
Hospital after LVAD (HM3) implantation between December 2017 and April 2019, who 
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underwent an echocardiographic ramp test when they were clinically stable. Patients were 
classified as clinically stable based on assessment of the treating cardiologist, had no inotropic 
or vasopressor therapy, and were ambulatory. 
8.2 Description of study methodology
8.2.1 Study I
Aim: 
To test the hypothesis that (1) levosimendan improves hemodynamics in advanced but 
stable, chronic, advanced HF and (2) that the response is dependent on baseline clinical and 
hemodynamic factors.
Methods:
All patients (n=23) received a single 24 h levosimendan infusion initially at a rate of 0.1 
μg/kg/min without bolus. Prior to, and immediately after the 24 h infusion, non-invasive 
hemodynamic evaluation was performed using Innocor® and blood samples for analyses 
of creatinine and NT-proBNP were collected. Estimated total peripheral resistance (eTPR) 
was calculated using the formula eTPR = [mean arterial pressure (MAP) – central venous 
pressure]/CO × 80. The estimated glomerular filtration rate (eGFR) was determined using the 
chronic kidney disease epidemiology collaboration formula (CKD-EPI) (177).
8.2.2 Study II
Aim:
We evaluated sST2 concentrations, correlations with biomarkers and echocardiographic 
measures of diastolic and systolic function, and associations with outcomes in HFpEF and 
HFrEF.
Methods:
The patients [HFpEF (n=86), HFrEF (n=86) and healthy controls (n=21)] underwent 
echocardiography in a stable state. Fasting blood samples were collected for measurement of 
sST2 and NT-proBNP. sST2 was analyzed by using Presage® ST2 Assay kit that quantitatively 
measures sST2 by enzyme-linked immunosorbant assay. NT-proBNP was analyzed by fully 
automated quantitative assay using Cobas®. Concentrations of sST2 and the associations 
with other relevant biomarkers and echocardiographic measures of diastolic and systolic 
function, and outcomes were assessed in HFpEF and HFrEF.
8.2.3 Study III
Aim:
To assess the differential impact of the steady (PAWPs) and pulsatile components (PAWPp) 
of PAWP on the PAC-PVR relationship in patients with HF.
 
Methods:
In 192 patients with echocardiographic and hemodynamic findings indicating HF, RHC 
waveforms were used to measure the pulsatile and steady components of the PAWP. PVR 
was calculated as [mean pulmonary artery pressure (PAPM) – mean pulmonary capillary 
wedge pressures (PAWPM)]/CO and expressed as mmHg•seconds•mL
−1. PAC was calculated 
as per the equation: PAC = SV/PAPP in mL•mmHg
−1; where: PAPP= pulmonary arterial pulse 
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pressure. The raw data of PAWP and PAP waveforms was futher analysed to measure the 
steady and pulsatile PAWP components. All patients underwent a standard echocardiographic 
examination 1-hour prior to RHC and provided fasting blood samples for analyses.
8.2.4 Study IV
Aim:
To test the hypotheses that echocardiographic ramp test post HM3 LVAD implantation 
improves LV unloading immediately after and 1-3 months after as compared to before the 
test and that speed adjustments do not worsen RV function.
Methods:
Echocardiographic ramp tests were performed pre discharge or as outpatient in the early 
postoperative phase when patients (n=14) were clinically stable. The ramp test was carried 
out by gradual increase of the LVAD speed by 100-400 revolutions per minute (RPM) at 
1-2-minute intervals with repeated acquisition of all echocardiographic and device parameters 
at each speed step in order to optimize pump speed. Optimal LVAD speed was set according 
to the current recommendations to adequately unload the LV while maintaining a minimal/
mild mitral regurgitation (MR), and intermittent aortic valve (AV) opening or closed AV, 
and reduction in left ventricular end-diastolic diameter (LVEDD), and for the follow-up 
measurement, also decreased NT-proBNP. Worsening RV function was defined as an increase 
in right ventricular end-diastolic diameter (RVEDD) or increase in tricuspid regurgitation 
(TR) or reduction in tricuspid annular plane systolic excursion (TAPSE) or an increase in 
central venous pressure (CVP) (judged by inferior vena cava (IVC) size and collapsibility) 
and, for the follow-up assessment, an increase in diuretic dose.
8.3 Statistics
Statistical analysis was performed using SPSS version 22.0 and 23.0 (SPSS Inc., Chicago, 
IL, USA). Continuous variables are displayed as median and lower and upper quartile (Q1; 
Q3). Categorical variables are shown as numbers (n) and percentages (%). A two-sided P 
value of <0.05 was considered statistically significant in all studies.
8.3.1 Study I
To test statistical significance between continuous variables the Mann–Whitney U test 
was used. Pre and post infusion data was compared through the Wilcoxon’s paired test. 
Association between baseline clinical and hemodynamic factors and the outcome change in 
CO was analysed using Spearman’s correlations. The temporal change of different variables 
in study I, was presented as median change and standard deviation (SD). 
 
8.3.2 Study II
Baseline data was compared using Mann-Whitney or Kruskal-Wallis test and Fisher’s exact 
test as appropriate. Spearman’s correlations were assessed between sST2, NT-proBNP, and 
eGFR in HFpEF and HFrEF as were echocardiographic parameters of systolic function and 
diastolic function/structural heart disease. The associations between sST2 and the composite 
outcomes in HFpEF and HFrEF respectively, were analyzed by Cox proportional hazards 
models and presented as hazard ratio (HR) and 95% confidence interval (CI) per log increase 




To demonstrate the relationship between PAC and PVR, a non-linear curve was fitted 
according to the hyperbolic formula: y = a/b + x. Curve fits were generated using MATLAB 
(version 9.4, R2018a; 2018, The MathWorks, Natick, MA). Continuous variables were 
compared using the Mann-Whitney U test.
 
8.3.4 Study IV
Wilcoxon’s paired test was used to compare median values of study variables before and after 
ramp test.
8.4 Ethical considerations
All studies complied with the Declaration of Helsinki and were approved by the regional 
ethical review board (178). Written informed consent was obtained from all participants in 
study I-II. Individual patient consent was not required or obtained in study III-IV since the 
studies were a retrospective analysis.




Table 1 details selected baseline characteristics of the 23 included patients. Patients had 
advanced HFrEF with a median (Q1; Q3) EF of 20 (15; 31) %, CO was 3.05 (2.8; 3.4) L/min, 
and NT-proBNP 3400 (1882; 6597) pg/ml. 
There was a significant increase of CO after a single levosimedan infusion from 3.05 (2.8; 
3.4) L/min to 3.45 (3.1; 4.2) L/min corresponding to a median change ± standard deviation 
of +9.8% ± 21.6%; p=0.026 (Figure 4). CO increase was attributed to an increased SV from 
48 (40; 53) to 52 (46; 61) mL/min, p=0.021 and heart rate was unchanged from 69 (62; 74) 
to 70 (61; 76) beats/min, p=0.159.
Table 1. Selected baseline characteristics for patients in Study 1. Continuous variables 
are presented as median, lower and upper quartiles (Q1; Q3). Categorical variables as 
numbers (n) and percentages.
Variable
Demographics (N=23)
Age (years) 56 (49; 64)
Female gender (n/%) 4/17
Hemodynamics and heart failure characteristics
Heart rate (beats/min) 69 (61; 73)
Mean blood pressure (mmHg) 79 (74; 87)
eGFR (ml/min/1.73 m2) 62 (35; 78)
eTPR ( dyn·s·cm−5) 1628 (1405; 2034)
BSA (m2) 2.0 (1.9; 2.2)
NYHA-class: IIIA / IIIB / IV (n) 4/18/1
Sinus rhythm (n/%) 8 / 35
Atrial fibrillation (n/%) 15 / 65
Device therapy
Pacemaker (n/%) 1 / 4
ICD (n/%) 6 / 21
CRT-P (n/%) 1 / 4
CRT-D (n/%) 15 / 65
Medical therapy
B-blockers (n/%) 22 /95
ACEI/ARB (n/%) 22 /95
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Figure 5 shows the effect of a single 24-hour levosimendan infusion on the other study 
variables. In summary, there was a significant decrease in NT-proBNP from 3400 (1882; 
6597) to 2530 (1108; 6410) pg/ml, p<0.001, eTPR from 1628 (1405; 2034) to 1343 (1151; 
1701) dyn·s·cm−5, p=0.004 and MAP from 79 (74; 87) to 74 (69; 81) mmHg, p =0.007. There 
was no difference in eGFR; 62 (35; 78) to 61 (40; 85) ml/min/1.73 m2, p=0.955.
Figure 4. Individual and median (Q1; Q3) cardiac output before and after levosimendan 
infusion (Study I).
Figure 5. Effect of a single 24-hour levosimendan infusion on NT-proBNP, eGFR, MAP and 
eTPR (Study I). 
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Figure 6A-F shows the lack of significant correlations between baseline characteristics or 
hemodynamic variables and the change in CO.
Figure 6. Absence of significant correlations between baseline cardiac output (CO) (A), 





Table 2 shows selected baseline characteristics of the 3 cohorts included. Patients with 
HFpEF were older, more often female, had lower NYHA class, higher MAP and body mass 
index (BMI) compared to HFrEF. Prevalence of co-morbidities such as atrial fibrillation and 
diabetes was similar between HFpEF and HFrEF. 
In HFpEF, left atrial volume index (LAVi) was median (Q1; Q3), 43 (37; 53) mL/m2 and LV 
mass index (LVMi) was 115 (95; 143) g/m2. Corresponding data in HFrEF were; LAVi 48 
(40; 73) mL/m2 and LVMi 146 (127; 184) g/m2. 
Table 2. Selected baseline characteristics; median, (Q1; Q3). Categorical variables as 
numbers (n) and percentages (Study II).









Age (years) 73 (67; 80) 63 (52; 68) 67 (59; 70) < 0.001 < 0.001 0.159 < 0.001
Gender male/female 42/44 (49/51) 70/16 (81/19) 9/12 (43/57) < 0.001 0.624 < 0.001 < 0.001
Medical history
Atrial fibrillation/flutter 49 (57) 45 (52) 0.541
Diabetes mellitus 28 (33) 25 (29) 0.621
PCI 9 (11) 20 (23) 0.026
NYHA I 19(22) 1 (1)
<0.001
NYHA II 47(55) 4 (5)
NYHA III 20 (23) 67 (80)
NYHA IV 0           14 (11)
Clinical Measurements
BMI (kg/m2) 29 (25;34) 27 (23;30) 25 (22;26) 0.001 <0.001 0.043 <0.001
MAP (mmHg) 100 (92;107) 82 (74;93) 94 (89;103) <0.001 0.111 <0.001 <0.001
HR (beats/min) 70 (60;80) 70 (60;75) 0.482
LVEF (%) 64 (58;68) 21 (15;28) <0.001
LVEDD (mm) 47 (43;53) 66 (61;75) <0.001
Treatment
ARB/ACE-I 67 (78) 77 (90) 0.037
Beta blocker 69 (80) 85 (99) <0.001
MRA 18 (21) 58 (67) <0.001
Loop diuretic 61 (71) 75 (87) 0.009
Laboratory
sST2 (µg/L) 23 (17; 31) 35 (23; 52) 25 (21; 32) <0.001 0.145 0.029 <0.001
NT-proBNP (ng/L) 1000 (465;2335) 3290 (1405;6115) 67 (31;110) <0.001 <0.001 <0.001 <0.001
eGFR (mL/min/1.73m2) 68(50;81) 58 (42;73) 82 (71;91) 0.036 0.006 <0.001 <0.001
PCI; pecutaneous coronary intervention
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Crude sST2 levels were higher in HFrEF compared to HFpEF and controls, median (Q1; 
Q3), 35 (23; 52), 23 (17; 31) and 25 (21; 32) µg/L respectively (overall p<0.001) (Figure 7). 
As depicted in Figure 8, levels of sST2 increased with worsening HF severity assessed as 
NYHA class in both LVEF categories.
Figure 7. Crude sST2 concentrations in HFpEF, HFrEF and controls, p-value denotes 
comparison between groups (Study II). 
Figure 8. sST2 concentrations by NYHA class in HFpEF and HFrEF, p-values for comparison 
between NYHA class in HFpEF (I vs. III) and HFrEF (II vs. IV) (Study II). 
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Table 3 shows Spearman’s correlations between sST2 and demographic/echocardiographic 
data in HFpEF, HFrEF, and controls.
Association between sST2 and outcomes in HFpEF and HFrEF
Median (Q1; Q3) follow-up time was 522 (232; 1089) days in HFpEF and 204 (55; 421) 
days in HFrEF. In the HFpEF group, 11 patients (13%) died and the composite outcome of 
all-cause death or HF hospitalization occurred in 36 patients (42%). In the HFrEF group, 28 
patients (33%) died and the composite outcome of death from any cause, implantation of 
LVAD or HTx occurred in 56 patients (65%).
In both HFpEF and HFrEF, sST2 was significantly associated with the composite outcome 
in crude analyses (HR per log increase 10.04 [95% CI 1.89-53.44], p=0.007) and (HR 3.28 
[95% CI 1.06-10.16], p=0.039) respectively (Figure 9a and b). The association persisted 
after adjustment for age, sex, and NYHA class. 
Table 3. Correlations between sST2 and variables in HFpEF, HFrEF and controls (Study II).
Variable
sST2
HFpEF n=86 HFrEF n=86 Controls n=21
r p-value r p-value r p-value
NT-proBNP (ng/L)  0.392             <0.001 0.466              <0.001 -0.020             0.931
Age (years)  0.116             0.295 0.043               0.698  0.215             0.350
NYHA class  0.307             0.005 0.270               0.014
eGFR (mL/min/1.73m2) -0.073             0.513 -0.224              0.044 -0.141             0.542
MAP (mmHg)  0.047             0.668 -0.015              0.901 -0.350             0.120
BMI  (kg/m2)  0.116             0.301 -0.035              0.755 -0.115             0.501
E/e’ (average)  0.148             0.248 -0.096              0.523
LAVi (mL/m²)  0.276             0.019 0.247               0.224   
LVMi (mL/m²) -0.005             0.795 0.622               0.018
LVEF (%) -0.057             0.634 0.005               0.962
Figure 9. Kaplan-Meyer estimates of survival free from HF hospitalization in HFpEF (a) 
and survival free from HTx or LVAD in HFrEF (b) comparing sST2 above and below median 
in HFpEF and HFrEF respectively. Association with the composite endpoint in HFpEF and 
HFrEF analyzed with Cox Regression, HR per log increase in sST2, 95% confidence interval, 
and p-value depicted in each graph (Study II).
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9.3 Study III
Selected baseline characteristics of the 192 patients are presented in Table 4. Median (Q1; 
Q3) age was 64 (52; 74) years, 81 (42%) were women, 80 (42%) patients were classified as 
HFpEF, and the majority being significantly symptomatic (75% in NYHA III). 
Table 4. Selected baseline clinical characteristics; median, (Q1; Q3). Categorical variables 
as numbers (n) and percentages (%) (Study III).
Demographics (n=192)
Age (years) 64 (52;74)
Gender male/female (n/%) 111/81 (58/42)
Medical history
Ischemic heart disease (n/%) 50 (26)
Diabetes mellitus (n/%) 39 (20)
Hypertension (n/%) 109 (57)
Atrial fibrillation/flutter (n/%) 104 (54)
NYHA I 7 (3.5)
NYHA II 32 (17)
NYHA III 144 (75)
NYHA IV 9 (4.5)
Diagnosis
HFpEF 80 (42)
Ischemic cardiomyopathy 33 (17.2)
Dilated cardiomyopathy 51 (26.6)
Hypertrophic cardiomyopathy 5 (2.6)
Restrictive cardiomyopathy 16 (8.3)
Clinical measurements
BMI (kg/m2) 27 (23;30)
SBP (mmHg) 110 (95;134)
DBP (mmHg) 63 (57;72)
HR (beats/min) 69 (59;79)
Treatment
ARB/ACE-I 149 (78)




NT-proBNP (ng/L) 2120 (868;3580)
eGFR (mL/min/1.73m2) 58 (41;79)
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Table 5 shows selected baseline echocardiographic and hemodynamic data. Median (Q1; 
Q3) EF was 46 (25; 60) %, cardiac index (CI) 2.2 (1.8; 2.6) L/min/m², PVR 0.15 (0.10; 0.22) 
mmHg•seconds•mL−1, and PAC 2.4 (1.7; 3.5) mL•mmHg−1.
Impact of the PAWPM and the V-wave amplitude on the PAC-PVR relationship 
In accordance with previous findings, there was a hyperbolic and inverse relationship between 
PAC and PVR (Curve fit: y=0.587/0.073 + x, R²=0.56); (Figure 10).  





LVMi (g/m²) 108 (80;150)
LAVi (mL/m²) 53 (40;67)
E’(cm/sec) 7 (5.5;8.5)
E/A 1.7 (1.3;2.2)
E/e’ (average) 13 (10;18)
RA area (cm²) 22 (17;27)
RVSP (mmHg) 45 (37;58)
TAPSE (mm) 15 (11;19)
Hemodynamic measurements
CI (L/min/m²) 2.2 (1.8;2.6)
PVR (mmHg•seconds/mL) 0.15 (0.096;0.216)
PAC (mL/mmHg) 2.4 (1.7;3.5)
PAWP-mean (mmHg) 18 (14;24)
PAWP-A (mmHg) 19 (15;25)
PAWP-V (mmHg) 24 (17;32)
PAP-mean (mmHg) 30 (22;37)
PAP-systolic (mmHg) 44 (35;57)
PAP-diastolic (mmHg) 18 (13;24)
RAP-mean (mmHg) 8.5 (5;14)
E, transmitral early diastolic filling velocity; A, transmitral  late diastolic filling velocity; E’, average value of lateral and septal early 
diastolic myocardial velocity; E/A, ratio between the early transmitral diastolic filling velocity to late diastolic filling velocity; RA , 
right atrium; RVSP, right ventricular systolic pressure; RAP, right atrial pressure.
Figure 10. PAC-PVR relationship in the study cohort compared to best curve fit given by 
Tedford and colleagues (Study III).
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As illustrated in Figure 11, elevated PAWPM (>18 mmHg) yielded a shift of the hyperbolic 
curve fit downward and to the left, such that PAC was lower for similar PVR values in 
patients with higher PAWPM. Similarly, patients with peak systolic LAP above the median 
value for the whole group (V-wave > 24 mmHg) demonstrated a curve fit shifted downward 
and to the left as compared to the corresponding group with lower peak V-waves (Figure 11). 
Impact of LAP pulsatility on the PAC-PVR relationship
As depicted in figure 12a, the group of patients with higher levels of steady PAWP (> 
16.7 mmHg) demonstrated a slight shift of the PAC-PVR fit curve downward and to the 
left (y=0.671/0.119 + x, R²=0.41) compared to those with lower steady PAWP values 
(y=0.570/0.059 + x, R²=0.61).  However, the RC-time did not differ significantly between 
the two groups (0.35 (0.23; 0.48) vs. 0.38 (0.31; 0.47)) p= 0.078 (Table 6).
 
As illustrated in figure 12b, the shift of the curve fit for the PAC-PVR association for the 
patient cohort with higher pulsatile PAWP component (> 3.5 mmHg) was more pronounced 
(y=0.584/0.102 + x, R²=0.53) as compared to the corresponding group with lower levels 
of systolic pulsatility (y=0.683/0.078 + x, R²=0.54). Additionally, the subgroup with higher 
pulsatile PAWP component displayed a significantly shorter RC-time [0.31 (0.23; 0.40) vs. 
0.44 (0.34; 0.54)] p<0.001 (Table 6).
Figure 12 a-b. Effects of elevated PAWP steady and pulsatile components on PAC-PVR 
relationship (Study III).
Figure 11. Effects of elevated PAWPM and V-wave on PAC-PVR relationship (Study III). 
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We proceeded by dichotomizing the study cohort as based upon the ratio of the steady and 
pulsatile PAWP components. As provided in the Table 6, there was no significant difference 
in the PAWPM between the 2 groups. However, the RC time was significantly lower in the 
subgroup with elevated ratio, which in turn was driven by a significant rise in pulmonary 
pulse pressure (PP) (p=0.006). 
9.4 Study IV
Baseline characteristics at implantation
The majority of patients included in this study were men (93%), median (Q1; Q3) age was 
49 (41; 59) years. Median LVEF was 16 (14; 20) %, LVEDD 67 (61; 77) mm, and TAPSE 
was 13 (13; 20) mm. Dilated cardiomyopathy was the main underlying cause of HF and 
accounted for 57 % of all causes and 64 % had Interagency Registry for Mechanically 
Assisted Circulatory Support (INTERMACS) III. The main indication for LVAD was bridge 
to decision (BTD) (50 %).
Pre-RAMP characteristics
Intraoperatively, the patients had a low median LVAD speed of 4800 (4500; 4850) RPM, 
which was gradually increased in the post-operative period during the time preceding the 
ramp test to 4950 (4875; 5225) RPM as depicted in table 7. Median pre-RAMP LVEDD 
was 58 (55; 70) mm, RVEDD 42 (40; 48) mm, and TAPSE 8 (6.5; 9.5) mm. Median time 
from implantation to ramp test was 27 (16; 56) days. Adequate LV unloading was present in 
only 6 (43%) patients out of 14 patients at pre-RAMP when applying all the 3 criteria for LV 
unloading (Table 8). 
Table 6. Selected baseline characteristics stratified according to pulsatile and steady PAWP 
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LV unloading and RV function during ramp testing
Maximum speed limit was not achieved during ramp testing; however, the achieved median 
(Q1; Q3) upper LVAD speed (Ramp-High) was 5550 (5375; 6025) RPM, which was 
significantly higher than pre-RAMP LVAD speed (p<0.001). Increases in LVAD speed were 
associated with a significant reduction of LVEDD to 53 (46; 63) mm (p<0.001) in 13 (93%) 
patients. Table 8 demonstrates the impact of acute changes in LVAD speed on LV unloading 
where 10 (71%) patients had adequate LV unloading at Ramp-High when applying all the 3 
criteria for LV unloading. Out of 14 patients, 1 patient had no reduction of LVEDD, 1 patient 
had moderate MR, 1 patient which had the AV constantly open and in 1 patient the AV was 
not visualized.
Ramp testing resulted in direct LVAD speed increase in 13 (93%) patients with a median speed 
change of 100 (100; 200) RPM. At Ramp-High, RV function did not worsen significantly; 
however, seven (50%) patients had increased TR severity but only 1 out of 7 increased to 
severe TR. Tables 7-8 and figure 15 illustrate the acute impact of RPM changes on LV 
unloading and RV function. 
Table 7. Characteristics before, during ramp testing, and at follow-up (final LVAD speed); 
median, (Q1; Q3) (Study IV). 









Pump speed (RPM) 4950 (4875;5225) 5550 (5375;6025) 5200 (5000;5425) <0.001 0.001
LVEDD (mm) 58 (55;70) 53 (46;63) 57 (49;62) <0.001 0.125
RVEDD (mm) 42 (40;48) 46 (42;50) 46 (40;47) 0.391 0.625
TAPSE (mm) 8 (6.5;9.5) 8 (6.5;10.5) 8 (7.5;10) 0.425 0.200
CVP (mmHg) 5 (4;10) 5 (5;11) 5 (5;10) 0.437 1.000
Furosemide (mg) 120 (80;260) 80 (20;220) 0.072
eGFR (mL/min/1.73m2) 45 (31;71) 52 (32;66) 0.855
NTproBNP (ng/L) 2320 (1845;3593) 1310 (812;2653) 0.002
Table 8. LV unloading at different time points; pre-RAMP, ramp-High, and final follow-up 
LVAD speed; n (%) (Study IV).
LVAD speed n Reduced 
LVEDD











14 13 (93%) 13 (93%) 8 (57%) 6 (43%) 11 (79%) 5 (36%)
Ramp-High vs. 
pre-RAMP
14 13 (93%) 13 (93%) 12 (86%) 10 (71%)
Final vs. 
pre-RAMP
13 9 (69%) 13 (100%) 7 (54%) 6 (46%) 12 (86%) 4 (31%)
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LV unloading and RV function at final LVAD speed (Speed at follow-up)
Median time from ramp test to follow-up echocardiography was 55 (47; 102) days. The 
median LVAD speed at the time of follow-up echocardiography was 5200 (5000; 5425) RPM, 
which was significantly higher than pre-RAMP LVAD speed (p=0.001) but lower than goal 
RPM which was 5375 (5100; 5700) RPM. One patient was transplanted before doing follow-
up echocardiographic examination and this patient was excluded from echocardiographic 
analysis at final LVAD speed. Ramp testing resulted in final follow-up LVAD speed increase 
in 11 (79%) patients and a median net change at the time of follow-up echocardiography of 
200 (200; 300) RPM. Figure 13 shows the median change of different study variables at final 
follow-up LVAD speed compared to pre-RAMP pump speed.
Figure 14 illustrates a reduction of LVEDD to 57 (49; 62) mm in association with increased 
LVAD speed but the reduction was not significant (p=0.125) compared to pre-RAMP, despite 
a significantly higher final follow-up LVAD speed.
Figure 13. Median change of RVEDD, TAPSE, eGFR, NTproBNP, and Furosemide dosage at 
final follow-up LVAD speed compared to pre-RAMP pump speed (Study IV).
Figure 14. Individual LVEDD at pre-RAMP and final follow-up LVAD speed (Study IV).
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Adequate LV unloading was achieved in 6 (46%) patients when applying all the 3 
echocardiographic criteria for LV unloading at the time of follow-up, and in 4 (31%) patients 
when all 4 criteria (including NT-proBNP) were applied (all of them had increased RPM 100-
300 at final speed compared to pre-RAMP (Table 8)). 
At the time of follow-up echocardiography, RV function had not worsened significantly and 
only one (8%) patient had increased TR severity (Table 7 and figure 15). Additionally, there 
was a non-significant reduction in daily Furosemide dose from 120 (80; 260) mg to 80 (20; 
220) mg (p=0.070).
Figure 15. LV unloading and RV function at final follow-up LVAD speed vs. pre-RAMP pump 




Multiple different invasive and non-invasive methodologies were useful in multiple 
different HF settings, to assess prognosis and optimize care.The principal findings of the 
four studies in this thesis are:
Study I: Levosimendan improved Innocor®-assessed CO and reduced NT-proBNP, MAP, 
and eTPR after a single infusion in advanced stable chronic HF, but no predictors of the 
levosimendan effect on CO that could be used for patient selection were identified.
Study II: In patients with HFpEF, compared to HFrEF, crude levels of sST2 were lower 
but potentially more strongly associated with outcomes. 
Study III: In HF patients, the PAC was reduced in a steeper manner for the same PVR 
value in patients with higher PAWP compared to patients with less pronounced PAWP 
elevations. We also demonstrated that the pulsatile rather than the steady PAWP component 
had a stronger impact on the PVR-PAC relationship in patients with HF. 
Study IV: LVAD speed adjustments after echocardiographic ramp testing resulted in 
optimized final follow-up LVAD speed, manifested as improved LVAD unloading achieved 
in an additional 21% of patients who were not originally optimized. This speed optimization 
did not worsen RV function. 
10.2 The use of levosimendan in heart failure
Levosimendan has an established role as short-term therapy in ADHF patients with low CO 
and evidence of end-organ dysfunction. It is the most frequently used inotropic agent in 
cardiology and internal medicine in Sweden (68) despite conflicting evidence on survival 
benefits (71-74). Furthermore, there has been an increasing interest in the last decade to use 
levosimendan repetitively or intermittently to provide periods of hemodynamic relief in 
patients with advanced HF waiting for LVAD/HTx or as a palliative care pathway. The use 
of levosimendan in repeated or intermittent cycles seems to have clinical benefits including 
reduction in NT-proBNP, and trends toward reduction in HF readmissions and probably 
HF-related mortality, but evidence is not uniform and there is lack of selection criteria to 
predict benefits from repeated or intermittent levosimendan therapy (77, 179, 180).
In study I, we studied the effects of a single infusion of levosimendan in advanced but stable 
chronic HF. Our findings of distinct improvements in hemodynamics and NT-proBNP in 
stable HF are novel but consistent with previous studies in ADHF, and suggest that the 
benefits in advanced but stable chronic HF may be mediated similarly to that in ADHF. 
However, we could not identify any clinical or hemodynamic predictors of levosimendan 
response, and thus the selection of patients for this expesnive and potentially harmful 
intervention remains difficult.  
10.3 The role of ST2 in heart failure
Presently there is no evidence-based therapy for HFpEF and there is an increasing interest in 
identifying biomarkers reflecting distinct and novel pathophysiological pathways (181), both 
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as a diagnostic tool and as markers for targets for future therapy. As mentioned earlier, sST2 
is one of the most promising novel biomarkers in HF and has a diagnostic capability and a 
prognostic potential independent or additive to other biomarkers in acute and chronic HF 
(125, 182-188). sST2 measurement is now recommended by American College of Cardiology 
and American Heart Association for additive risk stratification in ADHF and chronic HF 
(189). Furthermore, there is mounting evidence suggesting that serial sST2 measurements 
might have significant prognostic implications (129, 130).
Unlike NPs, sST2 is not confounded by age, renal function or BMI (190-193); however, it 
is inferior to NT-proBNP for diagnosis of acute HF (125, 194). Interestingly, the currently 
approved partition value of 35 µg/L to predict morbidity and mortality, is mainly based on 
studies of  HFrEF or studies in which HFrEF patients were dominant (185, 195, 196). Hence, 
studies in HFpEF are warranted.
In study II, our cohort demonstrated lower sST2 levels in patients with HFpEF (23 µg/L) 
than in other studies including patients with HFpEF, where the median values were 25-30 
µg/L (197, 198). In HFpEF patients, we found an association between sST2 levels and LAVi, 
which is an important prognostic predictor in HF, independent of LVEF. In both HFpEF and 
HFrEF sST2 was significantly associated with the composite outcome.
Study II adds to the existing evidence of sST2 as an independent prognostic marker not only 
in HFrEF but also in HFpEF and suggests a lower sST2 cut-off than 35 µg/L in HFpEF.  
10.4 The impact of PAWP on PAC-PVR relationship
The pulmonary circulation is a high flow/low-pressure system and the RV is vulnerable to 
increases in afterload. Increased RV afterload will contribute to RV dysfunction, which 
is associated with poor prognosis (157). The concept of RV afterload is frequently used in 
routine clinical practice, but is somewhat simplified by measuring only PA pressure and PVR 
rather than combining PVR and PAC which represent RV resistive and elastic components 
respectively (158, 159). Considering RV afterload in terms of PAC and PVR accounts for the 
pulsatility imposed by the cardiac cycle.
Study III, confirmed the finding of previous studies that there is an inverse and hyperbolic 
relationship between PAC and PVR (162-164, 166, 199-201) and that higher PAWP shifted 
the curve fit downward and leftward in HF patients. In particular, we explored the effects of 
elevated static and pulsatile LAP components inherent to the cardiac events and showed that 
the pulsatile pressure component of the LAP and not the steady component had a significant 
impact on the PAC-PVR relationship. It appears that the mechanism by which the phasic oscil-
lations of LAP affect the elastic properties of the pulmonary vascular tree might be ascribed 
to the resultant wave reflection as well as the subsequent distortion of the pulmonary pressure 
waveform. These findings introduce a new way of considering the hemodynamic consequenc-
es of elevated LAP in HF patients and may aid in the development of new treatments targeting 
both the steady and pulsatile components of PAWP.
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10.5 The usefulness of echocardiographic ramp test to optimize LVAD 
speed
Improved postoperative management and optimal LVAD speed are key elements to reduce 
adverse events, optimize hemodynamics and achieve adequate LV unloading. The main 
advantage of using echocardiographic ramp test over the hemodynamic approach is that it is 
easy, non-invasive and available in many clinics.
Study IV confirmed the positive impact of echocardiographic ramp test on LVAD speed 
optimization and LV unloading without worsening of RV function both during ramp testing 
and at the time of follow-up with echocardiography. Another important finding was that clinical 
stability did not necessarily implicate optimal LVAD speed and LV unloading. 
RV failure is a frequent and feared complication following LVAD implantation and is a 
major cause of postoperative morbidity and mortality (202). There is always a concern when 
optimizing LVAD unloading that the increase of LVAD speed will lead to increased venous 
return to the RV and a leftward septal shift resulting in unfavourable RV geometry. However, 
in Study IV, there were no signs of deteriorating RV function after LVAD speed optimization. 
This can partially be explained by decreased RV afterload secondary to increased LVAD speed 
(203, 204). Notably, it has been shown that higher LVAD speeds, beyond 5600 RPM in HM3, 
may affect the RV negatively as evidenced by increased RV preload and volumes and less 
favourable RV geometry using three-dimensional echocardiography during ramp testing (205). 
This may explain our findings of absent worsening RV function, since the achieved final speeds 
were lower than 5600 RPM. In conclusion, our findings advocate the use of echocardiographic 
ramp test to optimize LV unloading post LVAD implantation.
10.6 Limitations
10.6.1 Study I
The study was limited by the small sample size which did not allow meaningful assessment 
of outcomes such as quality of life or reaching transplantation. Another limitation is the 
lack of control group with placebo infusion and the findings may be due a placebo effect. 
However, in prior randomized trials, placebo has not affected CO or stroke volume (206, 
207). We used PBF as a surrogate for CO, which due to shunts may entail limitations for 
cross-sectional between-patient comparisons but is reliable for within-patient, changes over 
time, which was the purpose in our study.
10.6.2 Study II
A major limitation was the small sample size with, in particular, few patients in the control 
group. Additionally, the three cohorts were recruited in different settings and there was no 
specific echocardiography protocol in the HFrEF patients. Moreover, the outcome definitions 
in HFrEF and HFpEF differed. Hospitalisations were not included in HFrEF due to a too high 
event rate, while implantation of LVAD or HTx were considered as deterioration and included 
in the composite endpoint for HFrEF. Including LVAD and HTx as part of a composite 
endpoint is standard practice in HFrEF. The alternative, to censor patient at LVAD and HTx 
would underestimate risk in HFrEF, since censoring precludes subsequent competing events. 
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Furthermore, despite multivariable adjustment, it is difficult to compare HFpEF and HFrEF 
considering the different demographic and comorbidity profiles. The higher hazard ratio in 
HFpEF than in HFrEF is suggestive of a potentially stronger prognostic role of sST2, but 
by no means conclusive. Finally, it remains unclear whether the association between sST2 
concentrations and the prognosis of patients is HF specific, since sST2 concentrations may 
reflect other pathologic processes, such as pulmonary disease.
10.6.3 Study III
The study was limited by the single center nature of the study, and that RHCs were performed 
by different cardiologists and results must be regarded as hypothesis generating. However, 
the analysis of the data was performed by a single experienced invasive cardiologist whereby 
a standardized interpretation of hemodynamic data was performed. There was no control 
group of healthy individuals. Furthermore, we used the PP method to calculate PAC, is an 
indirect estimate which has been reported to overestimate PAC (163, 208, 209).There are 
alternative approaches to calculate PAC but they are impractical.
Moreover, despite the overall constant RC-time, there remains significant scatter around the 
curve fits which may be due to measurement error or potential unknown determinants.
10.6.4 Study IV
This study was limited by a small sample size, and despite being a single center study, the 
ramp tests were performed by different cardiologists. This does however; reflect real life 
clinical practice and the same criteria for ramp testing were applied in all patients. The 
echocardiographic examinations and evaluations were not blinded but we tried to reduce bias 
by having one single cardiologist interpreting all the examinations. The upper speed limit 
was not reached during ramp testing for different reasons; however, there was a significant 
increase of LVAD speed during ramp testing. Moreover, the duration of LVAD support before 
ramp test and the time to follow-up echocardiographic examinations varied which may have 
caused a time bias. Finally, no powerful clinical outcomes like readmission rates, functional 
capacity, and HRAEs were considered.
10.7 Future perspectives
HF remains a chronic, incurable, and generally irreversible syndrome despite the advances 
achieved in diagnosis, prognostication and treatment. Novel approaches are required to 
refine our diagnostic skills and improve our therapies. Considering the complexity of HF 
pathophysiology and care, increased awareness and better collaboration and shared care 
between the primary care physician and the cardiologist are needed to improve outcomes.  In 
Studies I-IV, patients with HF were referred from local HF hospital or primary care units to 
an advanced HF center, where further evaluation and therapies were planned and implemented 
such as RHC, echocardiography, LVAD, and levosimendan.
In HFrEF, the main challenges are the implementation and optimal utilization of existing 
evidence-guided therapies (1, 210). The non-invasive ramp test may be useful to optimize 
LV unloading and improve LVAD therapy in patients with advanced HF. Repetitive use of 
levosimendan may be acceptable as a palliative measure for patients with advanced and no 
other treatment options. 
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Regarding HFpEF, challenges remain both concerning diagnosis and therapy. The use of NPs 
to diagnose HFpEF with and without atrial fibrillation is already established (211) and has been 
added to the required criteria to diagnose HFpEF in the ESC guidelines (1). However, there 
is an increasing interest to use novel biomarkers that reflect other distinct pathophysiological 
pathways. sST2 and other biomarkers may be useful to diagnose, and risk stratify as well as 
serve as potential therapy targets and possibly individualize therapy (212, 213).  
RV failure is common in both HFpEF and HFrEF. Describing RV afterload in terms of PVR 
is an oversimplification of the pulmonary circulation. Beyond PVR, the measurement of PAC 
gives a more accurate assessment of RV afterload which may be useful for diagnosis, treatment 
monitoring and is a potential treatment target. 
          Hemodynamics, echocardiography, and biomarkers in heart failure
45
11. CONCLUSIONS
By assessing hemodynamics, echocardiography and biomarkers, it may be possible to gain 
a better understanding of the different HF phenotypes and the underlying physiology, which 
may introduce potential targets for future therapy. This current analysis of invasive and non-
invasive methods used to evaluate the cardiac performance has improved our understanding 
of these methods and added knowledge to the already existing evidence. 
Study I: Levosimendan was associated with improved hemodynamics in patients with 
advanced stable chronic HF. However, no predictor of the hemodynamic response was 
identified. 
Study II: In patients with HFpEF compared to HFrEF, crude levels of sST2 were lower but 
potentially more strongly associated with outcomes. 
Study III: The pulsatile rather than the steady PAWP component stands for the previously 
documented PAWP impact on the PAC-PVR relationship in HF patients.
Study IV: Echocardiographic ramp test allowed LVAD speed adjustment and optimization, 
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